文献速递临床试验与 GCP基础与转化研究

超重非酒精性脂肪性肝病参与者单核细胞中Omega-3在炎症与内质网应激中的作用机制:巴西Omega研究(BROS)随机对照试验研究方案

Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the "Brazilian Omega Study" (BROS)-a randomized controlled trial.
PubMed 文献 · Trials · 2021-12-18

本研究为三盲前瞻性随机对照试验,拟在19-75岁超重非酒精性脂肪性肝病(NAFLD)患者中比较补充2.2 g ω3(EPA+DHA)28天与安慰剂的效应,每组22人。研究将评估外周血单核细胞和中性粒细胞中炎症、内质网应激及ω3通路标志物的蛋白与基因表达,并探索Ffar4 R270H变异的分子反应与血脂谱。

要点

  • 三盲前瞻性随机对照试验,超重NAFLD患者随机接受2.2 g ω3(EPA+DHA)或安慰剂28天。
  • 主要评估PBMC和中性粒细胞中炎症、内质网应激及ω3通路标志物的蛋白与基因表达。
  • 探索Ffar4 R270H(rs116454156)变异的分子反应与血脂谱。

核心结论

  • 作者假设超重NAFLD参与者通过ω3补充与GPR120受体结合,可实现炎症与内质网应激信号通路的减弱。

研究设计与样本

  • 三盲前瞻性临床试验,在19-75岁超重男性和女性中开展,随机分为安慰剂组或补充组(2.2 g ω3 [EPA+DHA]),干预28天。
  • 样本量计算考虑TNFα蛋白变化和40%脱落率,每组获得22名个体。
  • 志愿者从NAFLD诊断患者中招募。

主要发现

  • 将在补充前后评估人体测量参数、食物摄入、体力活动、总血清脂质、全脂肪酸血谱和血糖。
  • 在PBMC和中性粒细胞中,将使用Western blot和RT-qPCR评估炎症标志物(TNFα、MCP1、IL1β、IL6、IL10、JNK和TAK1)、内质网应激标志物(ATF1、ATF6、IRE1、XBP1、CHOP、eIF2α、eIF4、HSP)及ω3通路标志物(GPR120、β-arrestin2、Tab1/2和TAK1)的蛋白含量与基因表达。
  • 参与者将使用TaqMan assay对R270H(rs116454156)变异进行基因分型。

关键数值与推荐

  • 补充剂量为2.2 g ω3(EPA+DHA),为期28天。
  • 急性处理(3小时)将评估ω3能否激活超重NAFLD参与者PBMC和白细胞中的GPR120。
  • 将探索Ffar4(GPR120基因)R270H变异的分子反应和血脂谱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The low-grade inflammation is pivotal in obesity and its comorbidities; however, the inflammatory proteins are out of target for traditional drug therapy. Omega-3 (ω3) fatty acids can modulate the downstream signaling of Toll-like receptor (TLR) and tumor necrosis factor-α receptor (TNFα) through GPR120, a G-protein-coupled receptor, a mechanism not yet elucidated in humans. This work aims to investigate if the ω3 supplementation, at a feasible level below the previously recommended level in the literature, is enough to disrupt the inflammation and endoplasmic reticulum stress (ER-stress), and also if in acute treatment (3 h) ω3 can activate the GPR120 in peripheral blood mononuclear cells (PBMC) and leukocytes from overweight non-alcoholic fatty liver disease (NAFLD) participants. The R270H variant of the Ffar4 (GPR120 gene) will also be explored about molecular responses and blood lipid profiles. A triple-blind, prospective clinical trial will be conducted in overweight men and women, aged 19-75 years, randomized into placebo or supplemented (2.2 g of ω3 [EPA+DHA]) groups for 28 days. For sample calculation, it was considered the variation of TNFα protein and a 40% dropout rate, obtaining 22 individuals in each group. Volunteers will be recruited among patients with NAFLD diagnosis. Anthropometric parameters, food intake, physical activity, total serum lipids, complete fatty acid blood profile, and glycemia will be evaluated pre- and post-supplementation. In the PBMC and neutrophils, the protein content and gene expression of markers related to inflammation (TNFα, MCP1, IL1β, IL6, IL10, JNK, and TAK1), ER-stress (ATF1, ATF6, IRE1, XBP1, CHOP, eIF2α, eIF4, HSP), and ω3 pathway (GPR120, β-arrestin2, Tab1/2, and TAK1) will be evaluated using Western blot and RT-qPCR. Participants will be genotyped for the R270H (rs116454156) variant using the TaqMan assay. It is hypothesized that attenuation of inflammation and ER-stress signaling pathways in overweight and NAFLD participants will be achieved through ω3 supplementation through binding to the GPR120 receptor. TRIAL REGISTRATION: ClinicalTrials.gov #RBR-7x8tbx. Registered on May 10, 2018, with the Brazilian Registry of Clinical Trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Batista ES, da Silva Rios T, Muñoz VR, et al. Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the "Brazilian Omega Study" (BROS)-a randomized controlled trial. Trials. 2021. PMID: 34922604. doi:10.1186/s13063-021-05702-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。